Summary
The B cell help function of CD4+ T cells may serve as an immunologic correlate of protective adaptive immunity. The quantitative assessment of the B cell help potential of CD4+ T cells is limited by the lack of suitable antigen-specific functional assays. Here, we describe a highly efficient antigen-specific T-B co-cultures for quantitative measurement of T-dependent B cell responses. Using Mycobacterium tuberculosis specific setup, we show that early priming and activation of CD4+ T cells is important for the mutualistic collaboration between antigen-specific T and B cells, which could be achieved by supplementing the co-cultures with autologous monocytes. We further show that monocyte-derived growth factors provide the impetus for productive T-B collaboration by conferring optimal survivability in the cultured cells. This study provides first evidence of C-type lectin domain family 11 member A (CLEC11A/SCGF) as an essential growth factor for B cell survival. Importantly, we demonstrate the successful translation of monocyte supplemented T-B co-cultures in qualitative assessment of SARS-CoV-2 specific memory CD4+ T cells by quantifying several correlates of productive T-B cross-talk like plasma cell output, secreted antibody, antibody secreting cells and IL21 secreting T cells. Thus, the method described here can provides qualitative assessment of SARS-CoV-2 spike CD4+ T cells after natural infection and can be applied to assess the B cell help function of memory CD4+ T cells generated in response to COVID-19 vaccine.
One sentence summary Qualitative assessment of antigen-specific CD4+ T cells for T-dependent B cell responses.
Competing Interest Statement
NG, AA are listed as inventor on procedure patent application no. 202111003148, submitted by National Institute of Immunology, that covers the use of described method for vaccine evaluation and adjuvant testing purposes. AS is listed as inventor on patent application no. 63/012,902, submitted by La Jolla Institute for Immunology, that covers the use of the megapools and peptides thereof for therapeutic and diagnostic purposes. Other authors declare that they have no competing interests.
Funding Statement
This work was financially supported by the Science and Engineering Research Board, DST grant (IPA/2020/000077) to NG, Department of Biotechnology grant (BT/PR30223/MED/2018) to NG and the core grant of National Institute of Immunology. Further support provided from NIH contract 75N9301900065 (to AS, DW) and NIH grant U01 (U01AI141995-03) to AS.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Boards of National Institute of Immunology (NII) and All India Institute of Medical Sciences (AIIMS), New Delhi, India.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available in the main text or the supplementary materials.
